New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:21 EDTVRX, AGNValeant recent weakness a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of Valeant (VRX) as a buying opportunity. After meeting with management, the firm has increased confidence in the company's ability to show accelerating top-line growth in the second half of 2014. It sees "compelling value" in Valeant shares regardless of the Allergan (AGN) outcome and keeps an Overweight rating on the stock with a $180 price target.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use